In bladder cancer, human epidermal growth factor receptor 2 (HER2) overexpression generally correlated with tumor progression and poor prognosis,10-12 but monoclonal antibodies and tyrosine kinase inhibitors targeting HER2 all failed to show clinical benefits in metastatic UC (mUC),13-15 except that afatinib showed some promising results in patients with mUC-harbored HER2 or HER3 genomic alteration,16,17 until the emergence of DV, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E (MMAE) via a cleavable linker. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.